About Dylan Sammut
Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.
by Dylan Sammut | Mar 30, 2020 1:45 pm | eHealth
In the eHealth sector, acquisitions for revenue cycle management (RCM) firms are usually headline-worthy deals, such as Frazier Healthcare Partners’ $250 million purchase of MedData, Inc. from Mednax (NYSE: MD) back in October 2019. RCM companies tend to service... Read More »
by Dylan Sammut | Mar 30, 2020 1:34 pm | Healthcare Market Updates
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most... Read More »
by Dylan Sammut | Mar 30, 2020 10:49 am | Behavioral Health Care
The spread of Covid-19 has forced most healthcare companies to hit pause on their M&A activity, especially those in the services sectors. Hospitals are overwhelmed and the Centers for Medicare & Medicaid Services issued guidelines that all elective surgeries,... Read More »
by Dylan Sammut | Mar 23, 2020 3:09 pm | Healthcare Market Updates
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most... Read More »
by Dylan Sammut | Mar 23, 2020 2:29 pm | Laboratories, MRI & Dialysis
After a year hiatus from the acquisition trail, Thermo Fisher Scientific Inc. (NYSE: TMO) is back with a big deal. Earlier in March, the medical diagnostics company announced it was acquiring QIAGEN N.V. (NYSE: QGEN) for $11.5 billion, or 23.8x EBITDA and 7.5x... Read More »